Vanda Pharmaceuticals has named James Kelly as senior vice president (SVP), chief financial officer (CFO), treasurer and secretary of the company. Kelly has more than 18 years of experience in financial and operating roles within the healthcare and pharmaceutical industry, most recently as vice president, controller at MedImmune. He will join Vanda on 13 December 2010.
Kelly has been a key member of MedImmune’s financial leadership team since 2006. He joined MedImmune as director of sales and marketing finance and progressed to the role of vice president, controller. Prior to MedImmune and beginning in 2000, Kelly was at Biogen Idec serving in research and development finance roles of increasing responsibility, most recently as the director of planning and operations. In that role, he was the finance leader for the global development organisation and head of business operations for clinical functions.
Kelly is a CFA charterholder and a member of the Association of Bioscience Financial Officers (ABFO). He received his MBA degree from Cornell University and his BSc degree in Business Administration from the University of Vermont.
The annual BNP Paribas Cash Management University kicked off on Thursday morning with treasury professionals congregating in Paris from across Europe.
APIs may be a solution to MT940 challenges, says Karen Fagan, treasury operation manager, for British television company, ITV.
Kicking off the first day of the Singapore Fintech Festival, issues with cryptocurrencies were addressed by MIT media labs director, Joi Ito, and panels of technology leaders discussed how they’re using data analytics.
Sibos 2017 day two highlights: Brexit and banking, and why ‘data is the new oil’ in financial services
How nation first politics can impact global financial organisations It’s clear that data and regulation are the two key topics that are ... read more